about
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formationThalidomide-induced teratogenesis: history and mechanismsBiomarkers, metabonomics, and drug development: can inborn errors of metabolism help in understanding drug toxicity?A HAND to TBX5 Explains the Link Between Thalidomide and Cardiac Diseases.Thalidomide-a notorious sedative to a wonder anticancer drug.Autism with ophthalmologic malformations: the plot thickens.Thalidomide: the tragedy of birth defects and the effective treatment of disease.Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice.Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding.Ca2+ promoted the low transformation efficiency of plasmid DNA exposed to PAH contaminants.Teratogenic effects of thalidomide: molecular mechanisms.Thalidomide: an old drug with new clinical applications.Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.The multi-systemic nature of diabetes mellitus: Genotype or phenotype?Progress report on the potential of angiogenesis inhibitors for neuro-oncology.Shoulder joint replacement can improve quality of life and outcome in patients with dysmelia: a case series.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Effects of anticancer drugs on transcription factor-DNA interactions.Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathwayLanreotide in the management of small bowel angioectasias: seven-year data from a tertiary centre.Anti‑angiogenic therapy for normalization of tumor vasculature: A potential effect of Buyang Huanwu decoction on nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potentialDermatologic therapeutics: thalidomide. A practical guide.Front line treatment of elderly multiple myeloma in the era of novel agents.Multicenter investigation of lifestyle-related diseases and visceral disorders in thalidomide embryopathy at around 50 years of age.Dental pulp stem cells in regenerative dentistry.Disruption of embryonic vascular development in predictive toxicology.Advancing the science of environmental exposures during pregnancy and the gene-environment through the National Children's Study.Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.Therapeutic effects of thalidomide in hematologic disorders: a review.Salvage therapy of multiple myeloma: the new generation drugs.Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others.Modulation of cereblon levels by anti-myeloma agents.A unique perylene-based DNA intercalator: localization in cell nuclei and inhibition of cancer cells and tumors.Transport of thalidomide by the human intestinal caco-2 monolayers.Identifying problematic drugs based on the characteristics of their targetsHuman cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.The effect of thalidomide in chicken embryos.Racemates revisited: heterochiral assemblies and the example of DL-thalidomide.Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide.Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma.
P2860
Q24653215-758001BA-94B4-41C1-A090-B6E1B9BFF7F7Q28085087-EF05C96F-841B-43EE-898D-D807E5972EFBQ28751300-E0140B66-0DA4-4CA8-8B04-9F0875FA310BQ33683998-7538868E-98A0-44C4-91FD-B4747C191C5BQ33956871-26AC312E-6BB7-412D-AFAC-5B41FA053450Q34123480-3E4FBF5B-CD8F-499E-979F-ABF1E299B737Q34179690-6419331D-5D34-4878-A4F4-23043CB6764AQ34382640-2040D088-0250-419B-B1D8-76000CD09BEDQ34606176-772E355F-4894-4012-BAFC-804C13882C32Q34618688-364A85F0-4E39-428D-A406-99334DAAEE9BQ34660391-9E38999C-BC84-43B7-B5BC-D25F148A1A75Q34798767-00FCE3E3-8AA6-4ABD-A43E-0521BDFF416BQ35175287-87AFBE65-BD37-4D18-B57E-D0304E247EA8Q35919282-D49FA7E6-A6E7-4F45-8BAD-39CC1BB24B10Q35964419-A8C9CB9D-8DE3-4FB9-990F-D3C924200D04Q36000164-BF73DD5F-164D-4F8A-8433-871D60DCFA10Q36061821-D2994D2D-1460-4AE1-A4D8-DCF7ED3162BBQ36158697-F2A5FBEC-2477-410C-878D-B872CC4CA519Q36309724-170E9B24-0937-47CA-A746-20D6D0DC8F1CQ36372377-7F36C96E-E446-4F70-9341-70A1F3E12859Q36623880-C51D894C-BF59-42E0-BC03-2FC57F3269BAQ36986014-88A439AC-E8EE-4052-84A9-9810F379FB5BQ37303213-5C214544-5743-460F-B4A6-442F89B4949DQ37505457-E767F77B-98D9-46DC-92CD-C9BFA0C34FBDQ37832691-C7E2C84A-4478-4691-A643-72F83DB9D244Q37978259-02C56976-5423-413E-8006-5B8F45521D80Q38055237-DF3ED0D8-FB3F-4881-841D-7510E223ADEFQ38074017-45F0A359-0F4E-48A7-AE4B-7C201949396FQ38121762-C30BFE0A-8EF4-4994-BBED-2056FC7DED54Q38223433-9A253DD8-9CFD-481C-828D-E4993E364754Q38649220-FE7E303A-F14B-4647-A78E-372A782B5AAAQ38888980-862F9487-5AF3-457D-AC0A-6C17A8933941Q38979797-8DC78B4C-9326-40AA-B9BA-FF218EF7179BQ40398700-5F95BFEA-2233-43F5-956D-4604E4C4410AQ40520056-1AF3E29F-D280-4F34-9D8A-9317B1AEEBD1Q41966805-7FAD1C29-9041-406D-83CE-5FD49C1ACAC0Q41994803-51C14954-FBCC-4895-AB73-85C7778B317DQ43478203-81CD1CC3-F0C5-4611-AFF2-8EA0AEC726E9Q43953684-072F5075-D5BB-4CAB-AF3B-E1103CBA5EEAQ44041377-C390339E-898C-4EE6-9FF2-80F077BEFFBE
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Mechanism of action in thalidomide teratogenesis.
@ast
Mechanism of action in thalidomide teratogenesis.
@en
type
label
Mechanism of action in thalidomide teratogenesis.
@ast
Mechanism of action in thalidomide teratogenesis.
@en
prefLabel
Mechanism of action in thalidomide teratogenesis.
@ast
Mechanism of action in thalidomide teratogenesis.
@en
P2093
P1476
Mechanism of action in thalidomide teratogenesis.
@en
P2093
Fillmore BJ
Stephens TD
P304
P356
10.1016/S0006-2952(99)00388-3
P407
P577
2000-06-01T00:00:00Z